I was coordinator of the software development of a project in the European Commission’ Telematic Applications Programme, DG XIII entitled “The Black Sea Tele Diab System (BSTD)”. The project was the result of a collaboration between members of the BSTD consortium, made up of the following partners: University of Sheffield (project coordinator) and University of Hull, UK; Research Institute and Diabetes Center, Greece; Institute of Diabetes, Nutrition and Metabolic Diseases, “N. Paulescu” and the Romanian Society Clinical Engineering and Medical Computing, Bucharest, Romania; Gorky State Medical University, Ukraine; Centre for Pathology, Chisinau, Moldova.
This system was carefully constructed and developed to meet the requirements to encourage clinicians to abandon paper records in favor of a fully-computerized healthcare record system and to promote the electronic exchange of healthcare information between clinicians and scientists in countries of the Black Sea area. The system was developed using a modular design and object oriented method approach. It was developped based on the Good European Health Record (GEHR) Architecture that faithfully preserving the data as originally intended, as well as permitting analysis of the data, which can come from many sources using an XML exchange method.
The GEHR structure is very comprehensive, data items being stored in a number of related tables that are held in a MS Access database. The software for the system has been developed in Microsoft Visual C++ and when combined with the database, it provides an application that is fast and well integrated with the Windows environment. Development of the system has followed a stepwise approach with validation of the architecture and the incorporation of feedback from users at each key stage.
There are five major work areas: patient records, reports, graphs, Diabetes Aggregated Data (DAD) and administration. Each of these contains a number of individual application/functions which are serviced by the relational tables that store the patient details, clinical measurements, doctors and user information. The Patient Records Function offers options for the management of the EHCRs (creation/correction/visualisation), such as: registration of a new patient and entry of the first record or sheet; the recording of a new sheet; the correction/visualisation of the sheet; the recording of data about the patient’s death, etc. The System Administration Function allows: Definition of the health care facility; definition of persons as users or system managers; management of passwords and access rights for the users; definition of measurement units; limited customisation of the user interface.
The FORA Mobile Care Station (MCS) features Bluetooth enabled devices for measuring blood glucose, blood pressure, temperature, weight and pulse oxygen. Devices transmit data to the iFORA CS PointClickCare iPad app then seamlessly and instantly to the PointClickCare EMR system. Learn more at ForaCare.com/mcs
The FORA Mobile Care Station (MCS) features Bluetooth enabled devices for measuring blood glucose, blood pressure, temperature, weight and pulse oxygen. Devices transmit data to the iFORA CS PointClickCare iPad app then seamlessly and instantly to the PointClickCare EMR system. Learn more at ForaCare.com/mcs
We are specializing in medical supplies, especially through research and development, production and export.
Supported by staff with the capacity to introduce top-of-the-line products and the passion for the well-being of people all over the world, we will continue to challenge ourselves to become the company, which gives value to society.
By basing all our activities on our business principles of competition in quality rather than quantity, original products rather than imitations, and creation of innovative products rather than extension of existing ones.
Hic13 c parker continuna dcap abstract don walker award winnerJanna Guinen
Presentation abstract on the Disaster Cardiovascular Prevention Network, an interoperable remote cardiovascular monitoring program launched for evacuees following the Great Japan Earthquake of 2011.
Do you have a medical device that treats or diagnoses a life-threatening disease? If yes, your device may be eligible for an expedited review pathway called the Breakthrough Devices Program. The FDA defines a breakthrough device as any device (or device-led combination product) that will “provide for more effective treatment or diagnosis of life-threatening or irreversibility debilitating diseases or conditions”...
The status of the HIV Case Based Surveillance project in Uganda presented at the WHO Workshop to release and disseminate guidelines for Strengthening HIV Patient Monitoring Case Surveillance and Reporting
Presentation on what it takes to get a clinical study off the ground in the UK along with some info on the impact of directive 2007/47/EC will have on clinical data requirements
Wireless Infusion Pumps: Securing Hospitals’ Most Ubiquitous Medical DevicePriyanka Aash
Imagine being dependent on a wireless infusion pump to receive the correct dosage of life-supporting medication. Now imagine the implications, were that pump to be maliciously hacked. In this session learn more about how to successfully secure these medical devices, based on work being conducted at the National Cybersecurity Center of Excellence (NCCoE) with premier health care organizations.
(Source: RSA USA 2016-San Francisco)
In accordance with the overall Elliot Project spirit, the Bulgarian Internet of Things eHealth case will also apply the Living Lab methodology, will use some elements of Cloud Computing, and will rely on a Web Intelligence system, which will consist of 7 parts: medical algorithms; expert systems; BI (Business Intelligent) system; databases; notification system; doctors’ Operational Advisory Portal and Patients’ Prevention Advisory Portal.
IoT Medical Devices | Topic #3 of PharmaLedger's 2nd Open Webinar PharmaLedger
In this IoT Medical Device Use Case presentation, you will find:
An introduction to IoT Medical Device use case presented by : Disa Lee Choun (UCB) and Francesca Rocchi (Bambino Gesù Children Hospital)
The current state and challenges of data collection from medical devices
The advantages of IoT in Clinical Trials
PharmaLedger’s blockchain solution for the future state
Value added by PharmaLedger per actor involved
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
We are specializing in medical supplies, especially through research and development, production and export.
Supported by staff with the capacity to introduce top-of-the-line products and the passion for the well-being of people all over the world, we will continue to challenge ourselves to become the company, which gives value to society.
By basing all our activities on our business principles of competition in quality rather than quantity, original products rather than imitations, and creation of innovative products rather than extension of existing ones.
Hic13 c parker continuna dcap abstract don walker award winnerJanna Guinen
Presentation abstract on the Disaster Cardiovascular Prevention Network, an interoperable remote cardiovascular monitoring program launched for evacuees following the Great Japan Earthquake of 2011.
Do you have a medical device that treats or diagnoses a life-threatening disease? If yes, your device may be eligible for an expedited review pathway called the Breakthrough Devices Program. The FDA defines a breakthrough device as any device (or device-led combination product) that will “provide for more effective treatment or diagnosis of life-threatening or irreversibility debilitating diseases or conditions”...
The status of the HIV Case Based Surveillance project in Uganda presented at the WHO Workshop to release and disseminate guidelines for Strengthening HIV Patient Monitoring Case Surveillance and Reporting
Presentation on what it takes to get a clinical study off the ground in the UK along with some info on the impact of directive 2007/47/EC will have on clinical data requirements
Wireless Infusion Pumps: Securing Hospitals’ Most Ubiquitous Medical DevicePriyanka Aash
Imagine being dependent on a wireless infusion pump to receive the correct dosage of life-supporting medication. Now imagine the implications, were that pump to be maliciously hacked. In this session learn more about how to successfully secure these medical devices, based on work being conducted at the National Cybersecurity Center of Excellence (NCCoE) with premier health care organizations.
(Source: RSA USA 2016-San Francisco)
In accordance with the overall Elliot Project spirit, the Bulgarian Internet of Things eHealth case will also apply the Living Lab methodology, will use some elements of Cloud Computing, and will rely on a Web Intelligence system, which will consist of 7 parts: medical algorithms; expert systems; BI (Business Intelligent) system; databases; notification system; doctors’ Operational Advisory Portal and Patients’ Prevention Advisory Portal.
IoT Medical Devices | Topic #3 of PharmaLedger's 2nd Open Webinar PharmaLedger
In this IoT Medical Device Use Case presentation, you will find:
An introduction to IoT Medical Device use case presented by : Disa Lee Choun (UCB) and Francesca Rocchi (Bambino Gesù Children Hospital)
The current state and challenges of data collection from medical devices
The advantages of IoT in Clinical Trials
PharmaLedger’s blockchain solution for the future state
Value added by PharmaLedger per actor involved
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Health Informatics - Transforming healthcare delivery in Hong Kong. Presented by Dr Ngai-Tseung Cheung, Head of Information Technology and Health Informatics/Chief Medical Informatics Officer, Hong Kong Hospital Authority, at HINZ 2014, 11 November 2014, 9.15am, Plenary Room
Insights into the Canadian eHealth Landscape - MaRS Future of MedicineMaRS Discovery District
In recognition of the need to develop a national digital health strategy and to co-ordinate activity across the country, the Conference of Deputy Ministers established Canada Health Infoway in 2001.
This lecture describes Infoway’s role and the progress that it and its jurisdictional partners have made over the last decade. It outlines the challenges to achieving our collective goal of using technology to improve the health of Canadians and describes key enablers that must be in place for us to be successful. It also contains the results of recent public opinion research conducted with Canadians and healthcare providers and outlines the priorities for moving forward and the opportunities for action.
Leveraging emerging standards for patient engagement pchamHealth2015
Patients are playing an increasingly important role in creating relevant healthcare data about themselves using mobile devices and applications. It is important this data can move with them securely throughout a healthcare ecosystem. The increased use of medical devices and mobile applications opens the dialogue around open source and non-proprietary standards with complementing policies.
Process Automation in Telemedicine - The Italian PerspectiveDenis Gagné
Presented by Baxter, with the participation of Telemedicine Observatory by ALTEMS (Università Cattolica del Sacro Cuore, Rome).
Stefano Collatina, Country Head Baxter Italy
Prof. Fabrizio Ferrara, Universita Cattolica del Sacro Cuore
Simone Naso, Digital Health Specialist, Baxter Italy
Health care delivery in Italy represents a number of challenges, including the regulatory requirements and the regional differences. Telemedicine has the potential to provide more cost-effective care, especially for vulnerable populations such as the elderly. In this webinar the unique needs of Italy will be discussed and how they can be addressed by standards-based process automation.
Zigbee based wearable remote healthcare monitoring system for elderly patientsijwmn
Remote health care monitoring system (RHCMS) has drawn considerable attentions for the last decade. As
the aging population are increasing and at the same time the health care cost is skyrocketing there has
been a need to monitor a patient from a remote location. Moreover, many people of the World are out of
the reach of existing healthcare systems. To solve these problems many research and commercial versions
of RHCMS have been proposed and implemented till now. In these systems the performance was the main
issue in order to accurately measure, record, and analyze patients’ data. With the ascent of wireless
network RHCMS can be widely deployed to monitor the health condition of a patient inside and outside of
the hospitals. In this work we present a ZigBee based wireless healthcare monitoring system that can
provide real time online information about the health condition of a patient. The proposed system is able to
send alarming messages to the healthcare professional about the patient’s critical condition. In addition
the proposed system can send reports to a patient monitoring system, which can be used by the healthcare
professionals to make necessary medical advices from anywhere of the World at any time.
Decision Support System for clinical practice created on the basis of the Un...blejyants
The company Socmedica developing an expert system of decision support for medical information systems. The product is aimed at solving the problem of medical errors.
PharmaLedger Official Presentation OverviewPharmaLedger
Download the Official PharmaLedger Project presentation, which introduces the project, its organisation and summarises the use cases.
In this downloadable presentation, you can find:
An introduction to the PharmaLedger project
PharmaLedger consortium
PharmaLedger objectives
Project organisation and governance
PharmaLedger platform overview
PharmaLedger selected use cases
Project roadmap
Value chain of use cases
Clinical Supply Chain Traceability use case summary
Supply Chain – Finished Goods Traceability use case summary
Supply Chain – E-Leaflet | EPI use case summary
Supply Chain – Anti-Counterfeiting use case summary
Clinical Trial – E-Consent use case summary
Healthdata – Medical Device IoT use case summary
Clinical Trial – Recruitment use case summary
Healthdata – Personalised Medicine use case summary
--
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
2. 2
BSTD AIMSBSTD AIMS
Promote medical informatics in Eastern EuropePromote medical informatics in Eastern Europe
and New Indepenedent Statesand New Indepenedent States
Software package to store information relating toSoftware package to store information relating to
patients with diabetespatients with diabetes
Provide framework for monitoring the outcome ofProvide framework for monitoring the outcome of
diabetes carediabetes care
3. 3
Electronic Health Care RecordsElectronic Health Care Records
Single subject of careSingle subject of care
Owned by particular organisationOwned by particular organisation
Medico-legal recordMedico-legal record
Appropriate access rightsAppropriate access rights
Provision for exchange of informationProvision for exchange of information
Global distributed recordGlobal distributed record
Mirror paper recordsMirror paper records
4. 4
Good European Health Record -Good European Health Record -
GEHRGEHR
First complete data structure for EHCRsFirst complete data structure for EHCRs
Ability to incorporate a wide range of data typesAbility to incorporate a wide range of data types
Facility to transmit medical records safely acrossFacility to transmit medical records safely across
telecommunications networkstelecommunications networks
Incorporation of mechanisms for translation ofIncorporation of mechanisms for translation of
the information into different languagesthe information into different languages
Support for the process of clinical care andSupport for the process of clinical care and
medical educationmedical education
5. 5
BSTDBSTDGOMGOM modelmodel - transaction- transaction
‘’‘’information recorded about a patient by a single
author in one institution at one point in time’
Interaction with HCR by a HCP at one point in time
Authorising HCP commits the transaction
Permanent record that cannot be erased
6. 6
Functional AspectsFunctional Aspects
The main menu.
• Only authorised
persons may have
access to the
system.
• These
administrative
functions are not
normally visible.
11. 11
Comparative meaningfulComparative meaningful
benchmarking auditbenchmarking audit
Nephropathy
Not KnownNo NephropathyNephropathy
Count
1000
800
600
400
200
0
COUNTRY
1
2
3
4
BLINDNESS
Not KnownNot BlindBlind
Count
1000
800
600
400
200
0
COUNTRY
1
2
3
4
12. 12
User FeedbackUser Feedback
Evaluated in two phasesEvaluated in two phases
• pre- and post- installation, Bucharestpre- and post- installation, Bucharest
2670 Diabcare BIS completed2670 Diabcare BIS completed
High degree of satisfaction among usersHigh degree of satisfaction among users
Key observations included:Key observations included:
• no negative impact on clinical care providedno negative impact on clinical care provided
• units of measurement varied between centresunits of measurement varied between centres
• some further interface improvements identifiedsome further interface improvements identified
• some additional fields felt desirablesome additional fields felt desirable
13. 13
WHO FeedbackWHO Feedback
The software project has succeeded in deliveringThe software project has succeeded in delivering
a competent piece of diabetes clinic software, ina competent piece of diabetes clinic software, in
step with emerging standards.step with emerging standards.
The software is at a standard comparable withThe software is at a standard comparable with
clinic IT systems marketed in Western Europeclinic IT systems marketed in Western Europe
There is a need to act reasonably quickly to moveThere is a need to act reasonably quickly to move
to wider implementation, and move beyond theto wider implementation, and move beyond the
scope of the research program.scope of the research program.
14. 14
BSTD - SummaryBSTD - Summary
Good distribution (RO, UKR)Good distribution (RO, UKR)
High satisfaction rateHigh satisfaction rate
Interest from additional countriesInterest from additional countries
Data fed back to WHOData fed back to WHO
